Blood test clues could make antifungal dosing safer for transplant patients
NCT ID NCT07716878
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study looks back at medical records of transplant recipients (lung, kidney, liver, or bone marrow) who received the antifungal drug isavuconazole. Researchers want to understand why blood levels of the drug vary so much between patients and whether higher levels are linked to liver problems. By analyzing routine blood test results, they hope to find ways to personalize dosing and improve safety. The study does not test a new treatment but gathers information from standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isavuconazole
- What this could lead to
- If successful, this study could help doctors personalize isavuconazole dosing for transplant patients, reducing the risk of liver side effects while effectively preventing or treating fungal infections.
- What could go wrong
- This is a small, single-center observational study, not a controlled trial. Results may not apply to other hospitals or patient groups, and the findings are only associations, not proof of cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Blood markers may flag lung transplant danger — study investigates
- Your genes may hold the key to safer lung transplants
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- AI model could predict who needs a lung transplant for rare emphysema